Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.40 |
| ▸ | GRM6 | O15303 | 3/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.40 |
| ▸ | ARG2 | P78540 | 2/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10392022 | 1.00 | GRM2 (0.40) | GRM2ARG1GRM6GRM3ARG2 | |
| Hydrochloric Acid SCHEMBL3129049 | 0.98 | ARG1 (0.39) | GRM2ARG1GRM6GRM3ARG2 | |
| SCHEMBL2901770 | 0.94 | ARG1 (0.45) | GRM2ARG1GRM6GRM3ARG2 | |
| Hydrochloric Acid SCHEMBL1632919 | 0.92 | ARG1 (0.44) | GRM2ARG1GRM6GRM3ARG2 | |
| SCHEMBL13472248 | 0.85 | — | — | |
| SCHEMBL16594983 | 0.83 | EPHX1 (0.38) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL14676591 | 0.83 | GRM2 (0.47) | GRM2ARG1GRM6GRM3GRM8 | |
| SCHEMBL7432189 | 0.79 | HDAC4 (0.33) | — | |
| SCHEMBL19304322 | 0.79 | GRM2 (0.40) | GRM2ARG1GRM6GRM3ARG2 | |
| SCHEMBL12662227 | 0.79 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-3628677-B1 | METHOD FOR PREPARING A CYCLOPEPTIDE | UNIV NAT TSING HUA (TW) | 2021-11-10 | — | — | EP | disclosed |
| EP-3392262-B1 | CYCLOPEPTIDE, PHARMACEUTICAL OR COSMETIC COMPOSITION COMPRISING THE SAME AND METHOD FOR PREPARING THE SAME | UNIV NAT TSING HUA (TW) | 2021-08-18 | — | — | EP | disclosed |
| US-10851134-B2 | Method for preparing cyclopeptide | NATIONAL TSING HUA UNIVERSITY (TW) | 2020-12-01 | — | — | US | disclosed |
| WO-2020230711-A1 | VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER | 積水化学工業株式会社 | 2020-11-19 | — | — | WO | disclosed |
| US-20200339632-A1 | METHOD FOR PREPARING CYCLOPEPTIDE | NATIONAL TSING HUA UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| US-10745444-B2 | Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same | NATIONAL TSING HUA UNIVERSITY (TW) | 2020-08-18 | — | — | US | disclosed |
| EP-2879673-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014025709-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8269046-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1631633-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | Arizona Chemical Company (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960248-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2004106442-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEMICAL COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040231555-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2004-11-25 | — | — | US | disclosed |
| EP-0091596-A2 | Hydantoins, their preparation and application | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1983-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851134-B2 | Method for preparing cyclopeptide | PPIB, PPIA, PPIL1 | GRM2 4497/4885ARG1 3277/4885GRM6 4171/4885 |
| US-10745444-B2 | Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same | PSAP, PPIG, PPIB | GRM2 4609/4885ARG1 408/4885GRM6 4459/4885 |
| US-20200339632-A1 | METHOD FOR PREPARING CYCLOPEPTIDE | PPIB, PPIA, PPIL1 | GRM2 4497/4885ARG1 3277/4885GRM6 4171/4885 |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | FHIT, DDC, MNAT1 | GRM2 1395/4885ARG1 1045/4885GRM6 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.